|
Post by Admin on Mar 6, 2015 18:23:42 GMT -8
The FDA finally approved a bio-similar drug for Neupogen. This is a cancer fighting drug that is very costly and having a bio-similar option allows cancer patients that use Neupogen to receive a slight cheaper alternative. Neupogen is a drug that is used to help bolster his immune system, but its cost (even with insurance) is very high. Joseph Manghan, who has an advanced form of cancer called Ewing Sarcoma, uses the drug after chemotherapy treatments. His mother insurance covers the larger portion of the bill, but the drug still cost them 1,200 out of pocket. That coupled with the high insurance premiums, this drug is a costly expense that can have dire financial ramification. Here is a link to the article. FDA approves 1st biosimilar drug
|
|